GenSight Biologics announces presentation of bilateral visual recovery from GS010 (LUMEVOQ™) Phase III trials at the 46th annual meeting of NANOS

46th NANOS Annual Meeting, Amelia Island, Florida, US

GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history

The Quinze-Vingts Hospital and GenSight Biologics announce a first Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France

ESGCT 27th Annual Congress, Barcelona (Spain)

EVER 2019, Nice (FR)

3rd Annual Gene Therapy for Rare Disorders Europe, London (UK)

GenSight Biologics reports evidence of GS010 DNA transfer to contralateral eye of primates unilaterally injected with GS010 Gene Therapy

GenSight Biologics to present new GS010 data at the 2019 Annual Meeting of the American Academy of Ophthalmology

Future is now: Leaders in Ocular Gene Therapy Meeting, San Francisco (CA)